Wingtech Technology Co. Chairwoman Ruby Yang has warned that global chip supplies will remain at risk unless the Chinese company's control over Dutch chipmaker Nexperia BV is restored. In an interview with Bloomberg News, Yang, who took over as chair of the board in July, accused the Dutch government of breaching a bilateral investment treaty with China and claimed that local managers have sought personal gain from the crisis.
"Each day the dispute continues, the damage to the global industrial chain, international investment confidence and the shareholders deepens," Yang said. In her first interview with international media since the dispute became public in October, she rejected allegations of improperly transferring technology to China and reaffirmed demands to restore shareholder rights at Nexperia. Yang also claimed that the Dutch government and local executives collectively want to oust Wingtech, which has owned the Nijmegen-based chipmaker since 2019, calling the suspension of its control "a premeditated and unwarranted intervention."
The comments underscore the deep rifts at Nexperia and raise serious questions about the stability of supplies of components that are critical to the automotive and consumer electronics industries. From a supply chain perspective, Nexperia ships wafers from Europe for final assembly in Asia. Its largest facility is in China, which is currently not cooperating with the parent company. Although political tensions between China and the Dutch state have eased, the feud has continued at the corporate level.
As part of the fallout, Honda Motor Co. has warned that it plans to halt production at plants in Japan and China in the coming weeks because of shortages. From a supply chain perspective, OEMs reliant on the just-in-time production model are once again experiencing how a geopolitical shock at a single supplier node can shut down entire lines. Tier-1 suppliers such as Bosch, Continental and Aptiv are accelerating efforts to identify alternative sources, but in the power semiconductor segment, replacing Nexperia's footprint in the short term remains technically unfeasible.
